At some point, the positive de-risk pressure will overwhelm whatever or whoever's apprehension is out there.
Safety is strong, effacing is building across multiple indications.
Provide hope and reduce the suffering for those patients without treatment options now.
Ann: Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $381.6M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.5¢ | 25.5¢ | $189.7K | 731.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 37999 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 67000 | 2 |
View Market Depth
| Last trade - 16.10pm 04/08/2025 (20 minute delay) ? |
| IMM (ASX) Chart |